We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$11.9B
AUM Growth
+$1.4B
(+13%)
Cap. Flow
+$748M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
747
New
202
Increased
220
Reduced
153
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$134M |
| 2 |
STMicroelectronics
STM
|
+$103M |
| 3 |
Meta Platforms (Facebook)
META
|
+$89.9M |
| 4 |
MetLife
MET
|
+$71.9M |
| 5 |
Gilead Sciences
GILD
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$153M |
| 3 |
MRSH
Marsh
MRSH
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$91.8M |
| 5 |
Electronic Arts
EA
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.43% |
| 2 | Technology | 17.4% |
| 3 | Industrials | 8.07% |
| 4 | Energy | 6.4% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Keros Therapeutics
KROS
$201M
| $44.3M | 0.37% |
763,548
-12,297
| -2% | -$607K |
|
77
Broadcom
AVGO
$1.96T
| $44.3M | 0.37% |
256,870
+208,370
| +430% | +$33.4M |
|
|
SWTX
78
DELISTED
SpringWorks Therapeutics
SWTX
| $44.3M | 0.37% |
1,381,624
+19,225
| +1% | +$718K |
|
79
Vera Therapeutics
VERA
$2.22B
| $44.2M | 0.37% |
1,000,893
+51,976
| +5% | +$1.97M |
|
80
Microchip Technology
MCHP
$42.9B
| $44.2M | 0.37% |
+550,491
| New | +$45.4M |
|
81
Unum
UNM
$14.2B
| $43.7M | 0.37% |
734,525
+324,658
| +79% | +$17.6M |
|
82
Becton Dickinson
BDX
$46.2B
| $43M | 0.36% |
178,148
-84,225
| -32% | -$19.7M |
|
83
Mettler-Toledo International
MTD
$28.5B
| $42.9M | 0.36% |
28,637
-5,562
| -16% | -$7.81M |
|
84
Crescent Energy
CRGY
$3.76B
| $42.8M | 0.36% |
3,910,399
+2,298,690
| +143% | +$26.3M |
|
85
Boston Scientific
BSX
$70.3B
| $42.7M | 0.36% |
510,048
-521,585
| -51% | -$41.1M |
|
86
Emerson Electric
EMR
$85.7B
| $42.4M | 0.36% |
387,915
-239,577
| -38% | -$25.8M |
|
|
BPMC
87
DELISTED
Blueprint Medicines
BPMC
| $42M | 0.35% |
453,578
-426,569
| -48% | -$42.4M |
|
88
Hexcel
HXL
$7.76B
| $41.1M | 0.35% |
664,153
+317
| +0% | +$19.9K |
|
89
Vertiv
VRT
$105B
| $40.7M | 0.34% |
408,743
+370,518
| +969% | +$30.7M |
|
90
Immunovant
IMVT
$8.09B
| $40.3M | 0.34% |
1,414,977
-408,438
| -22% | -$12M |
|
91
Bristol-Myers Squibb
BMY
$132B
| $40.3M | 0.34% |
778,156
+14,984
| +2% | +$703K |
|
92
IBM
IBM
$215B
| $40.2M | 0.34% |
+181,720
| New | +$35.6M |
|
93
Nike
NKE
$61.7B
| $39.3M | 0.33% |
+444,031
| New | +$34.8M |
|
94
Micron Technology
MU
$997B
| $39.2M | 0.33% |
+378,110
| New | +$39.5M |
|
95
Zai Lab
ZLAB
$2.1B
| $38.8M | 0.33% |
1,607,962
-724,722
| -31% | -$13.7M |
|
|
AZPN
96
DELISTED
Aspen Technology Inc
AZPN
| $38.8M | 0.33% |
162,318
+77,052
| +90% | +$16.2M |
|
97
Johnson Controls International
JCI
$89.3B
| $37.8M | 0.32% |
487,135
-113,567
| -19% | -$7.97M |
|
|
AZEK
98
DELISTED
The AZEK Co
AZEK
| $37.8M | 0.32% |
807,294
+419,824
| +108% | +$18M |
|
|
ENV
99
DELISTED
ENVESTNET, INC.
ENV
| $37.6M | 0.32% |
+600,000
| New | +$37.4M |
|
|
K
100
DELISTED
Kellanova
K
| $37.1M | 0.31% |
+460,066
| New | +$32.7M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Woodline Partners held 747 positions worth $11.9B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Woodline Partners deployed $748M of net new capital in Q3 2024, opening 202 new positions and adding to 220 existing holdings. Its largest new stake was ASML: 149,876 shares worth $125M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 42% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $153M trimmed.
- Woodline Partners's largest Q3 2024 buy was ASML: 149,876 shares worth $125M.
- Woodline Partners added most to STMicroelectronics in Q3 2024, an estimated $103M increase.
- Woodline Partners's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $153M.
- Woodline Partners fully exited TE Connectivity in Q3 2024, selling an estimated $161M.
- Woodline Partners's ten largest holdings make up 12% of its $11.9B portfolio in Q3 2024.
- Woodline Partners opened 202 new positions and closed 161 in Q3 2024.
- Woodline Partners's portfolio value rose 13% quarter-over-quarter to $11.9B.
Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.